<?xml version="1.0" encoding="UTF-8" standalone="yes"?><dealRecordsOutput><serviceExecutionTime>248</serviceExecutionTime><Deal id="161942"><Title>Kymab and Bill &amp; Melinda Gates Foundation to develop KY-7001, KY-7002, KY-7003, KY-7006 and KY-7004 against Infectious disease  </Title><CompanyPrincipal id="1032580">Bill &amp; Melinda Gates Foundation</CompanyPrincipal><CompanyPartner id="1065894">Kymab Ltd</CompanyPartner><Type>Drug - Early Research/Development</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Payment Unspecified" max="0.0" min="0.0"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Unknown" max="0.0" min="0.0"/></ValuesToPartner><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>1783530</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1783530</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"/></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="746">Infectious disease</Indication></Indications><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="1593">Antimicrobial</Action></ActionsSecondary><Technologies><Technology id="168">Monoclonal antibody human</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="766">Parenteral formulation unspecified</Technology></Technologies><DateStart>2016-07-28T00:00:00Z</DateStart><DateEventMostRecent>2016-07-28T00:00:00Z</DateEventMostRecent><Drugs><Drug id="102988"><DrugNameDisplay>KY-7004</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="DR">Discovery</PhaseHighestNow></Drug><Drug id="102985"><DrugNameDisplay>KY-7001</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="DR">Discovery</PhaseHighestNow></Drug><Drug id="102986"><DrugNameDisplay>KY-7006</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="DR">Discovery</PhaseHighestNow></Drug><Drug id="102984"><DrugNameDisplay>KY-7003</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="DR">Discovery</PhaseHighestNow></Drug><Drug id="102983"><DrugNameDisplay>KY-7002</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="DR">Discovery</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;By July 2016, &lt;ulink linkType="Company" linkID="1032580"&gt;Bill &amp;amp; Melinda Gates Foundation&lt;/ulink&gt; had entered into an agreement with  &lt;ulink linkType="Company" linkID="1065894"&gt;Kymab&lt;/ulink&gt; to develop &lt;ulink linkType="Drug" linkID="102985"&gt;KY-7001&lt;/ulink&gt;,  &lt;ulink linkType="Drug" linkID="102983"&gt;KY-7002&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="102984"&gt;KY-7003&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="102986"&gt;KY-7006&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="102988"&gt;KY-7004&lt;/ulink&gt; against Infectious disease [&lt;ulink linkType="Reference" linkID="1783530"&gt;1783530&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2016-07-28T00:00:00Z</Date><Drugs><DrugLink id="102983" nameDisplay="KY-7002"/><DrugLink id="102984" nameDisplay="KY-7003"/><DrugLink id="102985" nameDisplay="KY-7001"/><DrugLink id="102986" nameDisplay="KY-7006"/><DrugLink id="102988" nameDisplay="KY-7004"/></Drugs><Stage id="DR">Discovery</Stage><StageNotes>&lt;para&gt;KY-7002 is in discovery stage.&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;- By July 2016, &lt;ulink linkType="Company" linkID="1032580"&gt;Bill &amp;amp; Melinda Gates Foundation&lt;/ulink&gt; had entered into an agreement with  &lt;ulink linkType="Company" linkID="1065894"&gt;Kymab&lt;/ulink&gt; to develop &lt;ulink linkType="Drug" linkID="102985"&gt;KY-7001&lt;/ulink&gt;,  &lt;ulink linkType="Drug" linkID="102983"&gt;KY-7002&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="102984"&gt;KY-7003&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="102986"&gt;KY-7006&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="102988"&gt;KY-7004&lt;/ulink&gt; against Infectious disease.&lt;/para&gt;&lt;para&gt;-  KY-7002 is a    fully human mAb therapeutic, developed using  Kymouse technology.&lt;/para&gt;&lt;para&gt;- Financial terms were undisclosed  [&lt;ulink linkType="Reference" linkID="1783530"&gt;1783530&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="1032580" type="Company"><TargetEntity id="4296505922" type="organizationId">Bill &amp; Melinda Gates Foundation Trust</TargetEntity></SourceEntity><SourceEntity id="1065894" type="Company"><TargetEntity id="5037142047" type="organizationId">Kymab Ltd</TargetEntity></SourceEntity><SourceEntity id="746" type="ciIndication"><TargetEntity id="10021789" type="MEDDRA"/><TargetEntity id="D007239" type="MeSH"/><TargetEntity id="-367065996" type="omicsDisease"/><TargetEntity id="799" type="siCondition"/></SourceEntity></CrossReferences></Deal><Deal id="222197"><Title>IntelliSyn to provide services for Epigenetix's small molecule epigenetic modulators for AD, anxiety disorder, autism and cancer</Title><CompanyPrincipal id="1113048">IntelliSyn Pharma</CompanyPrincipal><CompanyPartner id="1090595">Epigenetix Inc</CompanyPartner><Type>Drug - Development Services</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Payment Unspecified" max="0.0" min="0.0"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Unknown" max="0.0" min="0.0"/></ValuesToPartner><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>1868018</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1868018</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"/></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="14">Alzheimers disease</Indication><Indication id="25">Anxiety disorder</Indication><Indication id="423">Autism</Indication><Indication id="651">Cancer</Indication></Indications><ActionsPrimary><Action id="14742">Protein arginine N-methyltransferase modulator</Action><Action id="9672">Hypoxia inducible factor modulator</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="2942">Anxiolytic</Action><Action id="890">Oxytocin modulator</Action><Action id="1615">Neuroprotectant</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><DateStart>2016-10-31T00:00:00Z</DateStart><DateEventMostRecent>2016-10-31T00:00:00Z</DateEventMostRecent><Drugs><Drug id="91877"><DrugNameDisplay>oxytocin modulators (autism/anxiety), Epigenetix</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="DR">Discovery</PhaseHighestNow></Drug><Drug id="91878"><DrugNameDisplay>arginine methyl transferase modulators (cancer), Epigenetix</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="DR">Discovery</PhaseHighestNow></Drug><Drug id="91879"><DrugNameDisplay>amyloidogenesis modulators (Alzheimer's disease), Epigenetix</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="DR">Discovery</PhaseHighestNow></Drug><Drug id="91876"><DrugNameDisplay>hypoxia sensing transcriptional regulator modulators (cancer), Epigenetix</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="DR">Discovery</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;By  October 2016, &lt;ulink linkType="Company" linkID="1113048"&gt;IntelliSyn&lt;/ulink&gt; had entered into an agreement with &lt;ulink linkType="Company" linkID="1090595"&gt;Epigenetix&lt;/ulink&gt;   to provide services on efficacy of state-of-the-art chemoinformatic and structure-based methods, medicinal chemistry, along with in vitro and in vivo pharmacology and cancer models to design and validate small molecule epigenetic modulators including &lt;ulink linkType="Drug" linkID="91876"&gt;hypoxia sensing transcriptional regulator modulators&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="91878"&gt;arginine methyl transferase modulators&lt;/ulink&gt; against cancer, &lt;ulink linkType="Drug" linkID="91877"&gt;oxytocin modulators&lt;/ulink&gt; for autism/anxiety and &lt;ulink linkType="Drug" linkID="91879"&gt;amyloidogenesis modulators&lt;/ulink&gt; against Alzheimer's disease [&lt;ulink linkType="Reference" linkID="1868018"&gt;1868018&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2016-10-31T00:00:00Z</Date><Drugs><DrugLink id="91876" nameDisplay="hypoxia sensing transcriptional regulator modulators (cancer), Epigenetix"/><DrugLink id="91877" nameDisplay="oxytocin modulators (autism/anxiety), Epigenetix"/><DrugLink id="91878" nameDisplay="arginine methyl transferase modulators (cancer), Epigenetix"/><DrugLink id="91879" nameDisplay="amyloidogenesis modulators (Alzheimer's disease), Epigenetix"/></Drugs><Stage id="DR">Discovery</Stage><StageNotes>&lt;para&gt;The drugs was in preclinical stage.&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;- By  October 2016, &lt;ulink linkType="Company" linkID="1113048"&gt;IntelliSyn&lt;/ulink&gt; had entered into an agreement with &lt;ulink linkType="Company" linkID="1090595"&gt;Epigenetix&lt;/ulink&gt;   to provide services on efficacy of state-of-the-art chemoinformatic and structure-based methods, medicinal chemistry, along with in vitro and in vivo pharmacology and cancer models to design and validate small molecule epigenetic modulators including &lt;ulink linkType="Drug" linkID="91876"&gt;hypoxia sensing transcriptional regulator modulators&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="91878"&gt;arginine methyl transferase modulators&lt;/ulink&gt; against cancer, &lt;ulink linkType="Drug" linkID="91877"&gt;oxytocin modulators&lt;/ulink&gt; for autism/anxiety and &lt;ulink linkType="Drug" linkID="91879"&gt;amyloidogenesis modulators&lt;/ulink&gt; against Alzheimer's disease.&lt;/para&gt;&lt;para&gt;- The drug hypoxia-sensing transcriptional regulator is the  modulators  for the  treatment of cancer, was currently in preclinical stage.&lt;/para&gt;&lt;para&gt;- Arginine methyl transferase modulators, for the  treatment of cancer, was currently in preclinical stage.&lt;/para&gt;&lt;para&gt;- The oxytocin modulators for the  treatment of autism and anxiety, was currently in preclinical stage.&lt;/para&gt;&lt;para&gt;- The small molecule modulators of amyloidogenesis, for the  treatment of Alzheimer's disease, was currently in preclinical stage.&lt;/para&gt;&lt;para&gt;- Financial terms were undisclosed [&lt;ulink linkType="Reference" linkID="1868018"&gt;1868018&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"/><TargetEntity id="331.0" type="ICD9"/><TargetEntity id="10012271" type="MEDDRA"/><TargetEntity id="D000544" type="MeSH"/><TargetEntity id="-1268969445" type="omicsDisease"/><TargetEntity id="101" type="siCondition"/></SourceEntity><SourceEntity id="25" type="ciIndication"><TargetEntity id="10057666" type="MEDDRA"/><TargetEntity id="D001008" type="MeSH"/><TargetEntity id="-1384065283" type="omicsDisease"/><TargetEntity id="30" type="siCondition"/></SourceEntity><SourceEntity id="423" type="ciIndication"><TargetEntity id="F84.0" type="ICD10"/><TargetEntity id="10003805" type="MEDDRA"/><TargetEntity id="D001321" type="MeSH"/><TargetEntity id="-1744075483" type="omicsDisease"/><TargetEntity id="39" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity><SourceEntity id="9672" type="Action"><TargetEntity id="4316" type="Mechanism">Drugs Targeting Hypoxia Inducible Factor (HIF) Proteins</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="237590"><Title>University of Hawaii to research on Cardax's CDX-085 for anti-aging gene in mice      </Title><CompanyPrincipal id="20591">University of Hawaii</CompanyPrincipal><CompanyPartner id="1090617">Cardax Inc</CompanyPartner><Type>Drug - Early Research/Development</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Payment Unspecified" max="0.0" min="0.0"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Unknown" max="0.0" min="0.0"/></ValuesToPartner><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>1912543</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1912543</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"/></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="1042">Aging</Indication></Indications><ActionsPrimary><Action id="20413">FOXO3 gene stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="1652">Prodrug</Technology></Technologies><DateStart>2017-03-28T00:00:00Z</DateStart><DateEventMostRecent>2017-03-28T00:00:00Z</DateEventMostRecent><Drugs><Drug id="99920"><DrugNameDisplay>astaxanthin prodrug (inflammation), Cardax Pharmaceuticals</DrugNameDisplay><PhaseHighestStart id="PC">Preclinical</PhaseHighestStart><PhaseHighestNow id="NDR">No Development Reported</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;By March 2017, &lt;ulink linkType="Company" linkID="20591"&gt;University of Hawaii&lt;/ulink&gt; had entered into a collaboration to research on &lt;ulink linkType="Company" linkID="1090617"&gt;Cardax&lt;/ulink&gt;'s &lt;ulink linkType="Drug" linkID="99920"&gt;CDX-085 &lt;/ulink&gt; for anti-aging gene in mice  [&lt;ulink linkType="Reference" linkID="1912543"&gt;1912543&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2017-03-28T00:00:00Z</Date><Drugs><DrugLink id="99920" nameDisplay="astaxanthin prodrug (inflammation), Cardax Pharmaceuticals"/></Drugs><Stage id="PC">Preclinical</Stage><StageNotes>&lt;para&gt;CDX-085 in preclinical studies showed 90% increase in the  FOX03 gene expression in mice. &lt;/para&gt;</StageNotes><Summary>&lt;para&gt;- By March 2017, &lt;ulink linkType="Company" linkID="20591"&gt;University of Hawaii&lt;/ulink&gt; had entered into a collaboration to research on &lt;ulink linkType="Company" linkID="1090617"&gt;Cardax&lt;/ulink&gt;'s &lt;ulink linkType="Drug" linkID="99920"&gt;CDX-085 &lt;/ulink&gt; for anti-aging gene in mice.&lt;/para&gt;&lt;para&gt;- CDX-085  is a  prodrug of astaxanthin,  a FOXO3 gene stimulator  for the  treatment of reduction of tissue damage associated with inflammation.&lt;/para&gt;&lt;para&gt;- Financial terms were undisclosed     [&lt;ulink linkType="Reference" linkID="1912543"&gt;1912543&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="20591" type="Company"><TargetEntity id="4298217978" type="organizationId">University of Hawai'i System</TargetEntity></SourceEntity><SourceEntity id="1090617" type="Company"><TargetEntity id="5037930358" type="organizationId">Cardax Inc</TargetEntity></SourceEntity><SourceEntity id="1042" type="ciIndication"><TargetEntity id="D000375" type="MeSH"/><TargetEntity id="-423055417" type="omicsDisease"/><TargetEntity id="1182" type="siCondition"/></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="246812"><Title>NIAID to conduct a preclincial studies for AmpliPhi Biosciences' AB-SA01 against Staphylococcus aureus infection </Title><CompanyPrincipal id="20520">National Institute of Allergy and Infectious Diseases</CompanyPrincipal><CompanyPartner id="20320">Armata Pharmaceuticals Inc</CompanyPartner><Type>Drug - Development Services</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Payment Unspecified" max="0.0" min="0.0"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Unknown" max="0.0" min="0.0"/></ValuesToPartner><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>2030584</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>2030584</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"/></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="308">Staphylococcus aureus infection</Indication></Indications><ActionsSecondary><Action id="1594">Antibacterial</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="66">Antibiotic</Technology><Technology id="57">Bacteriophage recombinant</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="611">Dermatological formulation</Technology></Technologies><DateStart>2018-05-03T00:00:00Z</DateStart><DateEventMostRecent>2018-05-03T00:00:00Z</DateEventMostRecent><Drugs><Drug id="73624"><DrugNameDisplay>AP-SA01</DrugNameDisplay><PhaseHighestStart id="C1">Phase 1 Clinical</PhaseHighestStart><PhaseHighestNow id="C1">Phase 1 Clinical</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In May 2018, &lt;ulink linkType="Company" linkID="20520"&gt;National Institute of Allergy and Infectious Disease&lt;/ulink&gt; (NIAID) agreed to provide the therapeutic development services  for preclincial studies of  &lt;ulink linkType="Company" linkID="20320"&gt;AmpliPhi Biosciences&lt;/ulink&gt;' &lt;ulink linkType="Drug" linkID="73624"&gt;AB-SA01&lt;/ulink&gt; to treat  Staphylococcus aureus infection [&lt;ulink linkType="Reference" linkID="2030584"&gt;2030584&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2018-05-03T00:00:00Z</Date><Drugs><DrugLink id="73624" nameDisplay="AP-SA01"/></Drugs><Stage id="C1">Phase 1 Clinical</Stage><StageNotes>&lt;para&gt;AB-SA01 is in phase I clinical trial&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;- In May 2018, &lt;ulink linkType="Company" linkID="20520"&gt;National Institute of Allergy and Infectious Disease&lt;/ulink&gt; (NIAID) agreed to provide the therapeutic development services  for preclincial studies of  &lt;ulink linkType="Company" linkID="20320"&gt;AmpliPhi Biosciences&lt;/ulink&gt;' &lt;ulink linkType="Drug" linkID="73624"&gt;AB-SA01&lt;/ulink&gt; to treat  Staphylococcus aureus infection.&lt;/para&gt;&lt;para&gt;- AB-SA01 is a 3-phage investigational therapeutic being developed for treatment of serious and drug-resistant Staphylococcus aureus (S. aureus) infections. &lt;/para&gt;&lt;para&gt;- Financial terms were undisclosed  [&lt;ulink linkType="Reference" linkID="2030584"&gt;2030584&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="73624" type="Drug"><TargetEntity id="852050" type="siDrug">AP-SA01</TargetEntity></SourceEntity><SourceEntity id="20520" type="Company"><TargetEntity id="5035523514" type="organizationId">National Institute of Allergy and Infectious Diseases</TargetEntity></SourceEntity><SourceEntity id="20320" type="Company"><TargetEntity id="4295908105" type="organizationId">Armata Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="308" type="ciIndication"><TargetEntity id="4176" type="siCondition"/></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="249626"><Title>NIDA to award Titan funding to develop ProNeura based implantable formulation of Nalmefene for opioid addiction</Title><CompanyPrincipal id="20377">Titan Pharmaceuticals Inc</CompanyPrincipal><CompanyPartner id="19601">National Institute on Drug Abuse</CompanyPartner><Type>Drug - Funding</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="~" max="2.7" min="2.7"/><ValueProjected accuracy="~" max="13.4" min="13.4"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Unknown" max="0.0" min="0.0"/></ValuesToPartner><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>2070690</Reference><Type>R&amp;D Funding</Type><Value accuracy="~"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="6.7" usdExchangeRate="1.0" usdExchangeRatePeriod="2018 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>2070690</Reference><Type>R&amp;D Funding</Type><Value accuracy="~"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="6.7" usdExchangeRate="1.0" usdExchangeRatePeriod="2018 Q2">0.0</ReportedAmountMil></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="243">Opiate dependence</Indication></Indications><ActionsPrimary><Action id="288">Opioid receptor antagonist</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="560">Drug implant</Technology><Technology id="658">Subcutaneous drug implant</Technology><Technology id="589">Sustained release formulation</Technology></Technologies><DateStart>2018-09-10T00:00:00Z</DateStart><DateEventMostRecent>2018-09-10T00:00:00Z</DateEventMostRecent><Drugs><Drug id="107552"><DrugNameDisplay>nalmefene (sustained release/sc implant, ProNeura, opiate dependence), Titan Pharmaceuticals/Opiant Pharmaceuticals</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="DR">Discovery</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In September 2018, &lt;ulink linkType="Company" linkID="19601"&gt;National Institute on Drug Abuse&lt;/ulink&gt; (NIDA)  awarded &lt;ulink linkType="Company" linkID="20377"&gt;Titan Pharmaceuticals&lt;/ulink&gt; a two year grant to develop ProNeura based implantable formulation of &lt;ulink linkType="Drug" linkID="107552"&gt;Nalmefene&lt;/ulink&gt; for opioid addiction [&lt;ulink linkType="Reference" linkID="2070690"&gt;2070690&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2018-09-10T00:00:00Z</Date><Drugs><DrugLink id="107552" nameDisplay="nalmefene (sustained release/sc implant, ProNeura, opiate dependence), Titan Pharmaceuticals/Opiant Pharmaceuticals"/></Drugs><PaymentsToPrincipal><Payment><Reference id="2070690">2070690</Reference><Type>R&amp;D Funding</Type><Value><Accuracy sortorder="5">~</Accuracy><USDAmountMil exchangeRatePeriod="2018 Q2" exchangeRateUS="1">2.7</USDAmountMil></Value></Payment></PaymentsToPrincipal><Stage id="DR">Discovery</Stage><StageNotes>&lt;para&gt;Nalmefene in discovery&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;- In September 2018, &lt;ulink linkType="Company" linkID="19601"&gt;National Institute on Drug Abuse&lt;/ulink&gt; (NIDA)  awarded &lt;ulink linkType="Company" linkID="20377"&gt;Titan Pharmaceuticals&lt;/ulink&gt; a two year grant of approximately $6.7 million to develop ProNeura based implantable formulation of &lt;ulink linkType="Drug" linkID="107552"&gt;Nalmefene&lt;/ulink&gt; for opioid addiction.&lt;/para&gt;&lt;para&gt;- The grant would provide approximately $2.7 million for the project from now through August 31, 2019,  the remaining amount to be funded over the subsequent year, subject to satisfactory project progress, fund availability and certain other conditions [&lt;ulink linkType="Reference" linkID="2070690"&gt;2070690&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="19601" type="Company"><TargetEntity id="5007039687" type="organizationId">National Institute on Drug Abuse</TargetEntity></SourceEntity><SourceEntity id="20377" type="Company"><TargetEntity id="4295905095" type="organizationId">Titan Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="243" type="ciIndication"><TargetEntity id="F11.2" type="ICD10"/><TargetEntity id="D009293" type="MeSH"/><TargetEntity id="-1731206897" type="omicsDisease"/><TargetEntity id="1154" type="siCondition"/></SourceEntity><SourceEntity id="288" type="Action"><TargetEntity id="2599" type="Mechanism">Opioid Receptor Inverse Agonists</TargetEntity><TargetEntity id="2415" type="Mechanism">epsilon-Opioid Receptor Antagonists</TargetEntity><TargetEntity id="266" type="Mechanism">Opioid Receptor Antagonists</TargetEntity></SourceEntity></CrossReferences></Deal></dealRecordsOutput>